EGFR antagonists such as erlotinib, an EGFR inhibitor used in the treatment of lung and pancreatic cancers, are successful in inhibiting growth of these tumors even though resistance eventually develops (43). This evidence concerns the gene EGFR and pancreatic neoplasm.